Aluminium hydroxide

CLINICAL USE

Phosphate binding agent

Antacid

DOSE IN NORMAL RENAL FUNCTION

Phosphate binder: 4–20 capsules daily in

divided doses

Antacid: 1 capsule 4 times daily and at

bedtime

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
78

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
70–90

%Excreted unchanged in urine &nbsp &nbsp :
No data

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
No data

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :
No data

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp :
Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
Unknown dialysability. Dose as in
normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
Unknown dialysability. Dose as in
normal renal function

HDF/high flux &nbsp :
Unknown dialysability. Dose as in
normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:
Unknown dialysability. Dose as in
normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs
None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

K/DOQI guidelines caution that CKD 5

patients on chronic therapy may develop
aluminium toxicity; therefore best avoided
in all but short-term therapy (calcium
carbonate, calcium acetate, lanthanum or
sevelamer are used in chronic therapy)

Take/administer with or immediately

before meals

In patients undergoing chronic therapy

with aluminium hydroxide, serum
aluminium levels should be monitored

Tags: post-by-auto-php